Risk of VTE with hormonal contraceptives35
| . | Baseline* . | Pregnancy37 . | LNG-IUD . | Progestin-only pills . | Second-generation OCs . | Fourth-generation OCs . | Third-generation OCs . | First generation OCs† . |
|---|---|---|---|---|---|---|---|---|
| VTE risk‡ | 3 | 5-20 | 2 | 2-3 | 5-7 | 9-12 | 9-12 | 6-12 |
| . | Baseline* . | Pregnancy37 . | LNG-IUD . | Progestin-only pills . | Second-generation OCs . | Fourth-generation OCs . | Third-generation OCs . | First generation OCs† . |
|---|---|---|---|---|---|---|---|---|
| VTE risk‡ | 3 | 5-20 | 2 | 2-3 | 5-7 | 9-12 | 9-12 | 6-12 |
First-generation OCs contain lynestrenol or norethisterone; second-generation OCs contain levonorgestrel, norgestimate, or norgestrel; third-generation OCs contain desogestrel or gestodene; fourth-generation OCs contain chlormadinone acetate, cyproterone acetate, dienogest, or drospirenone.
OC, oral contraceptive.
Among women of reproductive age.36
First-generation OCs contain ≥50 µg ethinyl estradiol; second-, third-, and fourth-generation OCs contain <50 µg ethinyl estradiol.
Cases per 10 000 woman-years.